Quinolone-resistant Campylobacter Infections: Risk Factors and Clinical Consequences1 by Engberg, Jørgen et al.
We integrated data on quinolone and macrolide sus-
ceptibility patterns with epidemiologic and typing data from
Campylobacter jejuni and C. coli infections in two Danish
counties. The mean duration of illness was longer for 86
patients with quinolone-resistant C. jejuni infections (medi-
an 13.2 days) than for 381 patients with quinolone-sensitive
C. jejuni infections (median 10.3 days, p = 0.001). Foreign
travel, eating fresh poultry other than chicken and turkey,
and swimming were associated with increased risk for
quinolone-resistant C. jejuni infection. Eating fresh chicken
(of presumably Danish origin) was associated with a
decreased risk. Typing data showed an association
between strains from retail food products and broiler chick-
ens and quinolone-sensitive domestically acquired C. jeju-
ni infections. An association between treatment with a
fluoroquinolone before stool-specimen collection and hav-
ing a quinolone-resistant C. jejuni infection was not
observed.
C
ampylobacter is a leading cause of bacterial gastroen-
teritis in industrialized and developing countries
worldwide (1). Most Campylobacter infections need not
be treated with antimicrobial agents. However, in a subset
of patients Campylobacter  may cause severe complica-
tions and increased risk for death and therefore requires
treatment. A recent Danish study has shown that patients
with  Campylobacter infections have higher acute- and
long-term death rates than controls after coexisting condi-
tions were taken into account (2). The drug of choice is a
macrolide (e.g., erythromycin or a newer agent) for treat-
ment of enteric Campylobacter infections after the micro-
biologic diagnosis. However, for the empiric treatment of
adults with suspected bacterial gastroenteritis, the drug of
choice typically includes a fluoroquinolone (e.g.,
ciprofloxacin) because of their activity against almost all
enteric bacterial pathogens. Antimicrobial drug resistance
in Campylobacter infections, in particular to quinolones,
has increased dramatically in many countries during the
1990s as reviewed by Engberg et al. (3). According to a
recent published report by World Health Organization (4),
the sources of antimicrobial drug–resistant Campylobacter
strains and the clinical impact of such strains need to be
determined.
We conducted a 1-year prospective study to address the
prevalence of macrolide and quinolone resistance in
human Campylobacter isolates. Human isolates were com-
pared with isolates from retail food products and broiler
chickens. A systematic approach integrating standardized
epidemiologic, antimicrobial susceptibility, and typing
data was used. We also conducted a case-comparison study
to identify risk factors associated with acquiring
quinolone-resistant C. jejuni infections.
Materials and Methods
Surveillance and Susceptibility Testing of
Campylobacter Isolates
The study included all culture-positive Campylobacter
infections from May 1, 2001, through June 10, 2002, from
two counties with a catchment area of approximately 1.1
million persons (approximately one fifth of the Danish
population). The county of Copenhagen, a metropolitan
residential area, has a population of 619,000, and the coun-
ty of Funen, an island with both urban and rural areas, has
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patient enrolment from the county of Funen during May
and June 2002, patients from this county who were infect-
ed after April 31, 2002, were excluded. Epidemiologic data
were captured on self-completed standardized patient
questionnaires forwarded by the Danish Zoonosis Centre.
Patients were interviewed about clinical symptoms, travel
history, and exposuresto food, water, and animals in the 7
days before illness onset. Completed questionnaires were
returned to the Danish Zoonosis Centre and linked with
microbiologic data.
All isolates included in the study were tested for resist-
ance to nalidixic acid and erythromycin. All human iso-
lates from the county of Copenhagen and isolates obtained
from retail food products and broiler chickens were
screened by a disk-diffusion test using Oxoid disks on 5%
blood agar plates. On the basis of zone sizes, this method
grouped the isolates in two well-separated populations of
susceptible and resistant isolates with both antimicrobial
drugs. The few isolates that fell between these populations
were retested by using the standardized tablet diffusion
and E-test procedures described previously (5), with the
modifications that resistance to nalidixic acid was defined
as an MIC >64 mg/L for the MIC method and a zone size
<27 mm for the tablet method. All human isolates from the
county of Funen were tested by the standardized tablet dif-
fusion test with both antimicrobial drugs. Finally, all iso-
lates found to be resistant and sensitive to nalidixic acid
from our case-comparison study were retested by both the
standardized tablet diffusion and E-test procedure. 
Case-Comparison Study
In the second half of the study period (from December
1, 2001, to June 10, 2002), characteristics of patients with
quinolone-resistant and quinolone-sensitive C. jejuni
infections were compared. Each patient with a resistant
isolate was matched with two randomly selected patients
with sensitive isolates. Patients were matched on date of
specimen collection. 
Patients answered, either by phone or by mail, a short
additional questionnaire, which included questions about
use of fluoroquinolones the month before onset of illness,
use of fluoroquinolones after onset of illness but before
specimen collection, use of antimicrobial drugs after spec-
imen collection, and other clinical information. When
patients could not answer questions about exposure to flu-
oroquinolones before fecal sampling, the information was
gathered from their healthcare providers.
Food and Animal Isolates
As part of a national surveillance program, food sam-
ples from retail outlet stores were analyzed for
Campylobacter at the regional food safety authorities,
according to accredited methods of the Nordic Committee
on Food Analysis (6). The samples were taken from whole
poultry and different cuts of poultry (frozen and fresh),
including chicken and turkey. Samples of pork and beef
products were also analyzed. Imported as well as domestic
food products were sampled.
As part of a national surveillance program for
Campylobacter in broiler chickens, chickens were sampled
at slaughter and analyzed for Campylobacter. In this study,
isolates from broiler chicken farms located in Funen
County were included (one isolate per flock). Copenhagen
County does not have any broiler chicken farms. 
Serotyping and Molecular Subtyping of
Campylobacter Isolates
One isolate from the primary isolation on modified char-
coal cefoperazone deoxycholate agar (mCCDA) from each
patient, as well as one isolate from each retail food sample
and broiler chicken fecal sample were characterized at
Statens Serum Institut and the Danish Veterinary Institute.
Speciation, serotyping, and RiboPrinting (automated ribo-
typing) were undertaken as previously described (7,8), with
the following modifications for the RiboPrinting method:
1-µL eye needle was filled with bacterial culture and dis-
solved in 100 µL sample buffer. Ten microliters of 10 g/L
lysozyme was added, and the solution was left at 37°C for
10 min. From this solution, 30 µLwas transferred to a sam-
ple carrier for heat treatment. The RiboPrinter was run
according to the SEC protocol at 37°C for 2 h.
Statistical Analysis 
Conditional logistic regression was applied to calculate
a matched odds ratio for the exposure variables. Variables,
which reached a significance level of <0.15 in the univari-
ate analysis of the case comparison study, were selected for
the multiple logistic regression analysis. Stepwise condi-
tional logistic regression with a backward elimination pro-
cedure was conducted to obtain a reduced model. Variables
with a p value <0.05 were kept in the model. All excluded
variables were retested in the final model. The statistical
software SAS Release v.8.00 (SAS Institute Inc., Cary, NC)
and Epi Info version 6.04d (Centers for Disease Control
and Prevention, Atlanta, GA) were used to analyze the data.
Results
Surveillance and Resistance
Of 975 culture-confirmed Campylobacter infections in
the study, 177 (18.2%) were infected with a quinolone-
resistant isolate, whereas 3 (0.3%) isolates were erythro-
mycin-resistant. Linked microbiologic and epidemiologic
data were obtained from 678 (69.5%) patients. In total,
152 (22.4%) patients had been outside Denmark within 1
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cally acquired infections. The three erythromycin-resist-
ant isolates were all C. coli, two of them were also
quinolone-resistant, and these were both isolated from
travelers returning to Denmark from Spain and Portugal,
respectively. 
Quinolone resistance was significantly associated with
the origin of infection: 76 (50.0%) of 152 infections
among travelers returning to Denmark were quinolone-
resistant whereas 52 (9.9%) of 526 of domestically infect-
ed patients were infected with a quinolone-resistant strain
(p < 0.001) (Table 1). For both C. coli and C. jejuni, a sig-
nificantly higher proportion of quinolone-resistant infec-
tions was found among patients who had been abroad in
the week before onset of illness than among patients with
domestically acquired infections (risk ratio [RR] 9.3, 95%
confidence interval [CI] 1.4 to 63.8, p = 0.004 and RR 4.9,
CI 3.6 to 6.7, p < 0.001). A higher proportion of C. coli
than  C. jejuni infections were acquired abroad (48.3%
compared with 21.3% of C. jejuni). 
Foreign travel was associated with different preva-
lences of quinolone resistance, depending on destination
(Table 2). No travelers returning from other Scandinavian
countries hosted quinolone-resistant Campylobacter iso-
lates, whereas travel to a number of regions and subre-
gions, including southern Europe and Southeast Asia, was
significantly associated with a high proportion of
quinolone-resistant infections.
C. jejuni infections and C. coli infections did not differ
in severity, as assessed by frequency of diarrhea, blood in
stool, abdominal pain, fever, vomiting, mean duration of
illness, or admission to hospitals. However, the mean dura-
tion of illness was longer for the 86 patients with
quinolone-resistant C. jejuni infections and a known dura-
tion of illness (median 13.2 days) than for the 381 patients
with quinolone-sensitive C. jejuni infections and a known
duration of illness (median 10.3 days, p = 0.001). The
association with extended length of illness was independ-
ent of foreign travel. For domestically acquired infections,
the mean duration of illness was 12.4 and 10.4 days for
quinolone-resistant and quinolone-sensitive infections,
respectively. For comparison, the mean duration of illness
for travel-associated infections was 13.9 and 10.3 days for
quinolone-resistant and quinolone-sensitive infections,
respectively. For C. coli, no difference in mean duration of
illness was observed between quinolone-resistant and
quinolone-sensitive infections.
Case-Comparison Study
From December 1, 2001, to June 10, 2002, 42 patients
were infected by quinolone-resistant C. jejuni isolates,
and these patients were matched with 84 patients with
quinolone-sensitive isolates. No patients were connected
on epidemiologic grounds of a recognized outbreak. The
patients with quinolone-resistant isolates had a mean age
of 33 years (interquartile range 20–45 years), and a male-
to-female ratio of 1:1.2. For comparison, patients with
quinolone-resistant isolates in the larger study, which
were not included in the case-comparison study, had a
mean age of 31 years (interquartile range 20–45 years),
and a male-to-female ratio of 1:1.3. No strains changed
susceptibility category after being retested. However, one
case-patient was shown to be co-infected with two C. jeju-
ni strains with identical serotype and RiboGroup, but with
different susceptibility patterns, i.e., one strain was clear-
ly sensitive (MIC of quinolone = 2 mg/L), whereas the
MIC of quinolone for the other one was 128 to >256 mg/L
on multiple repeated testings. Subsequent nucleotide
sequence analysis indicated a normal consensus sequence
in the former and a Thr-86 to Ala-86 mutation and three
silent mutations in gyrA in the latter. The patient had not
been exposed to fluoroquinolones before stool specimen
collection.
Risk factors for a quinolone-resistant C. jejuni infection
identified in the univariate analysis and in the multiple
logistic regression analysis are presented in Table 3.
According to the multiple logistic regression analysis, the
only exposures independently associated with an increased
risk for quinolone-resistant C. jejuni infection were foreign
travel (OR = 16.81), eating fresh poultry other than chick-
en and turkey (OR = 19.10), and swimming (OR = 5.01).
Eating fresh chicken (of presumably Danish origin) was
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Table 1. Quinolone resistance by history of recent foreign travel and comparison with Campylobacter isolates from food products and 
broiler chickens 
Human (n = 678) 
Travel (n = 152)  Domestic (n = 526)  Food (n = 180)  Broiler chickens (n = 49) 
Species  Total   n  % resistant
 a  n  % resistant
 a  n  % resistant
 a  n  % resistant
 a 
C. jejuni  1,118  137  48.2  506  9.9  153  8.5  39  5.2 
C. coli  79  15  66.7  14  7.1  27  29.6  10  0 
C. lari  1  0  –  1  100  0  –  0  – 
C. spp
b  6  0  –  5  20  0  –  0  – 
Total  1,204  152  50.0  526  9.9  180  13.7  49  5.2 
aQuinlone-resistant isolates. 
aSpeciation not performed. associated with a decreased risk (OR = 0.04). Age group
did not affect the findings (younger or older than 15 years
of age) in either the univariate or the multiple logistic
regression analysis. 
The case-comparison study identified 12 quinolone-
resistant cases that were domestically acquired. However,
to determine the sources of infection for the domestically
acquired quinolone-resistant infections, an unmatched sub-
analysis on domestically acquired infections (quinolone-
resistant versus quinolone-sensitive) was performed.
Infections treated with fluoroquinolones before specimen
collection were excluded. In this model, the parameter esti-
mates did not change substantially from the primary
model, but because of the lower sample size, the confi-
dence intervals increased, and only eating fresh poultry
other than chicken and turkey had p value <0.05. In 10
(11.9%) of 84 domestically acquired infections, patients
reported eating fresh poultry other than chicken and turkey
compared with 4 (9.5%) of 42 infections in persons with
travel-related infections.
Overall, we found information on antimicrobial drugs
for 122 of 126 patients. Forty patients (32.8%) were treat-
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Table 2. Prevalence of quinolone resistance in Campylobacter isolates according to destination of foreign travel within 7 days before 
onset of illness
a 
Origin
b  No. of patients  Susceptible  Resistant  % resistant  RR  95% CI  p value 
Domestic (Denmark)  526  474  52  9.9  –  –  – 
Southern Europe  43  15  28  65.1  6.59  4.70 to 9.24  <0.001 
Northern Europe  17  17  0  0  –  –  – 
Western Europe  18  10  8  44.4  4.50  2.52 to 8.01  <0.001 
Central/East Europe  9  8  1  11.0  1.12  0.17 to 7.26  1.00 
East Mediterranean Europe
c  13  6  7  53.8  5.45  3.09 to 9.59  <0.001 
South Asia  12  5  7  58.3  5.90  3.43 to 10.16  <0.001 
Southeast Asia  13  2  11  84.6  8.56  6.05 to 12.11  <0.001 
Middle East
d  5  2  3  60.0  6.07  2.84 to 12.99  0.009 
Africa  5  3  2  40.0  4.05  1.34 to 12.21  0.08 
Other regions/subregions
e  17  9  8  47.1  4.76  2.70 to 8.39  <0.001 
No travel information   297  249  48  16.2  1.63  1.13 to 2.36  0.011 
aRelative risk (RR), p value, and 95% confidence interval (CI) were calculated for the different regions/subregions with domestically acquired infections as 
reference. 
bCountry grouping according to the World Tourism Organization (9). 
cSolely Turkey. 
dSolely Egypt. 
eOther regions/subregions each with less than five visits (% quinolone resistance): Australasia 1 (0); Caribbean 1 (0); North America 1 (0), South America 2 
(100); North Asia 2 (50); unknown destination 1 (0); multiple subregions/regions 9 (56). 
Table 3. Risk factors for infection with quinolone-resistant Campylobacter jejuni as compared with those for quinolone-sensitive C. 
jejuni
a 
Univariate analysis  Multivariate analysis  Patients with 
resistant isolates 
(n = 42) 
Patients with 
sensitive isolates 
(n = 84) 
Exposures  No.  (%)  No.  (%)  mOR  95% CI  p value  mOR  95% CI  p value 
Travel abroad within last 7 
days 
30  (71.4)  12  (14.3)  12.12  4.23 to 34.73  <0.0001  16.81  3.44 to 82.20  0.001 
Fluoroquinolone treatment 
after illness onset but 
before stool sample or 
4 weeks before 
symptom onset 
8  (19.1)  5  (6.0)  4.44  1.15 to 17.09  0.031  –  –  – 
Beef (not cold cuts)  27  (64.3)  73  (86.9)  0.31  0.13 to 0.73  0.008  –  –  – 
Fresh chicken  14  (33.3)  58  (69.6)  0.17  0.06 to 0.45  0.0004  0.04  0.004 to 0.39  0.005 
Fresh poultry other than 
chicken and turkey 
7  (16.7)  7  (8.3)  2.40  0.73 to 7.86  0.148  19.10  2.18 to 167.30  0.008 
Sausages  8  (19.1)  33  (39.3)  0.32  0.12 to 0.88  0.027  –  –  – 
Handling of raw meat   9  (21.4)  43  (51.2)  0.14  0.04 to 0.48  0.002  –  –  – 
Public water supply  19  (45.2)  66  (78.6)  0.17  0.06 to 0.46  0.001  –  –  – 
Swimming (pool, ocean, 
lake, or other places) 
20  (47.6)  16  (19.1)  3.22  1.48 to 7.00  0.003  5.01  1.14 to 21.99  0.033 
Animal contact  14  (33.3)  45  (53.6)  0.44  0.20 to 0.94  0.032  –  –  – 
aMatched odds ratio–univariate and multivariate analysis. mOR, matched odds ratio; CI, confidence interval.  ed with antimicrobial agents for their campylobacteriosis;
of these, 33 patients (27%) received a fluoroquinolone, 6
patients (4.9%) received a macrolide, and 1 patient (1%)
received both a fluoroquinolone and a macrolide for the C.
jejuni infection.
Campylobacter Isolates from Retail 
Food Products and Broiler Chickens
The human isolates were included in a database and
compared with 180 Campylobacter isolates obtained from
retail food products (chicken [n = 139], turkey [n = 39], and
pork [n = 2]) and 49 isolates from broiler chicken fecal
samples obtained from the same geographic area and time
period as the human isolates. Most (63%) food isolates
were from Danish-bred food animals; the remaining iso-
lates were from imported food from France (n = 48), Italy
(n = 7), and the United Kingdom (n = 9). The origin of three
chicken isolates was unknown. Of 180 isolates obtained
from food products of both domestic and foreign origin,
153 (85%) isolates and 27 (15%) isolates were C. jejuni and
C. coli, respectively (Table 1). Thirteen (8.5%) of 153 C.
jejuni isolates and 8 (29.6%) of 27 C. coli isolates were
resistant to nalidixic acid. Three (2.0%) of 153 C. jejuni
isolates and 5 (18.5%) of 27 C. coli isolates were resistant
to erythromycin. Two isolates (one C. jejuni and one C.
coli) from domestic chicken products were resistant to both
antimicrobial agents. A subanalysis of resistance status by
origin of 139 retail chicken products (domestic versus
imported) showed that 7 (8.0%) of 87 C. jejuni isolates and
three (60%) of five C. coli isolates from domestic raised
chicken products were resistant to nalidixic acid. Of iso-
lates from imported chicken products, 5 (14.7%) (3 isolates
from France and 2 isolates from the United Kingdom) of 34
C. jejuni isolates and 1 (10%) (from France) of 10 C. coli
isolates were resistant to nalidixic acid.
Of 49 isolates from broiler chicken fecal samples, 39
(79.6%) were C. jejuni and 10 (20.4%) were C. coli (Table
1). Two isolates (4.1%) (both C. jejuni) were nalidixic
acid–resistant; one was also erythromycin-resistant. Five
(10.2%) isolates (four C. jejuni, one C. coli) were erythro-
mycin-resistant.
Serotyping and Molecular Subtyping of Isolates
We found 133 combinations of serotypes and Ribo-
Groups (hereafter subtypes) among 496 typed isolates (10
isolates were not tested or nontypeable) from domestically
acquired C. jejuni infections (Table 4). Eighteen (13.5%)
subtypes were identified exclusively among quinolone-
resistant isolates, 102 (76.7%), exclusively among
quinolone-sensitive isolates, and 13 (9.8%) among both
resistant and sensitive isolates. 
Five of 11 subtypes of quinolone-resistant C. jejuni
found among isolates from retail food products, broiler
chickens, or both were also found among quinolone-resist-
ant domestically acquired C. jejuni isolates from humans,
and 34 of 88 subtypes of quinolone-sensitive C. jejuni
found among isolates from retail food products, broiler
chickens, or both were also found among quinolone-sensi-
tive domestically acquired C. jejuni isolates from humans.
Patients with domestically acquired quinolone-sensi-
tive C. jejuni infections were more likely to have a C. jeju-
ni subtype that was also identified among retail food
products and broiler chickens than were patients with
domestically acquired quinolone-resistant infections (270
of 444 vs. 15 of 51, RR = 2.07, CI 1.34 to 3.18, p < 0.001).
Discussion
Several studies have proposed a causal relation between
the veterinary use of fluoroquinolones in food production
and the increase in quinolone-resistant Campylobacter
infections in humans (10–14). However, it has been  argued
that use of fluoroquinolones in human medicine may be
driving the increasing quinolone resistance among human
Campylobacter isolates (15,16). Our study provides addi-
tional epidemiologic and microbiologic data to this discus-
sion.
Our case-comparison study identified three factors to
be independently associated with increased risk of attract-
ing a quinolone-resistant C. jejuni infection: foreign trav-
el, eating fresh poultry other than chicken and turkey, and
swimming. Eating fresh chicken was associated with a
decreased risk. 
A travel association for quinolone-resistant Campylo-
bacter infection has been reported from numerous countries
in recent years (14,17–20). A limitation of most studies,
apart from the Minnesota study (14), is that the epidemio-
logic information did not include a question on current or
recent treatment with fluoroquinolones before stool-speci-
men collection. Therefore, uncontrolled confounding might
have occurred. In our study, treatment with a fluoro-
quinolone before stool-specimen collection and having a
quinolone-resistant C. jejuni infection, though statistically
significant in the univariate analysis, was no longer signifi-
cant in the multivariate analysis (Table 3). This finding sug-
gests that quinolone use in humans is not the major selective
force for quinolone resistance among Campylobacter spp.
that cause human infections. However, use of fluoro-
quinolones in human medicine may still, to some degree,
contribute to quinolone resistance in Campylobacter. This
finding was instructively illustrated in our study: by an
error, two strains were recovered from one Campylobacter
episode, a fluoroquinolone-sensitive strain obtained from
the patient’s stool sample on December 7, 2001, and one
resistant strain (MIC > 256 mg/L) from the same patient’s
stool sample on December 14, 2001. The second stool spec-
imen was obtained after at least 3 days’ treatment with
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RiboGroup, and subsequent sequence analysis showed a
Thr-86 to Ile-86 mutation in gyrA, the most common iden-
tified mutation in quinolone-resistant C. jejuni field strains.
Treatment with quinolones has previously been shown to be
associated with isolation of a resistant strain (15,21–23), but
this case is, to our knowledge, the first documented clinical
case in which the exact mutation is presented by a compar-
ison of pre- and posttreatment gyrA genes. In the study by
Smith et al. in Minnesota (14), human exposure to a fluoro-
quinolone before stool specimen collection was identified
as a risk factor for quinolone-resistant C. jejuni infection,
but their study also showed that treatment with a fluoro-
quinolone before stool culture accounted for a maximum of
15% of resistant isolates in Minnesota during 1996 and
1998. Therefore, fluoroquinolone use in humans can (and
did in a small extent in this study) result in emergence of
quinolone resistance in the treated patient, but the treated
patient is unlikely to be a source of quinolone-resistant
Campylobacter for other people, because person-to-person
transmission of Campylobacter is not considered epidemio-
logically important.
In our study, eating fresh poultry other than chicken and
turkey was rare, but a significant risk factor for both
quinolone-resistant infections in general, and for domesti-
cally acquired quinolone-resistant infections. The type of
fresh poultry other than chicken and turkey was not speci-
fied in the questionnaire but could have been duck, goose,
or ostrich.
Swimming was also associated with an increased risk
for quinolone-resistant infections. The exposure was fre-
quently reported by travel-related infections (20 [48%] of
42), compared with domestically acquired infections (16
[19%] of 84). Patients were questioned about swimming in
pool, ocean, lake, or other places combined. Future studies
should specify the type of water more specifically.
Eating fresh chicken was associated with a decreased
risk for quinolone-resistant infections. The fresh chicken
was of presumably Danish origin, as most fresh chicken
eaten in Denmark is domestically raised. In addition, as
travelers often eat at restaurants, where information about
whether a served chicken is fresh or has been frozen is nor-
mally not available, patients who reported eating fresh
chicken were likely to have consumed it in Denmark. This
is supported by the fact that of 56 (67%) of 84 domestical-
ly acquired infections, patients reported eating fresh poul-
try compared with 17 (38%) of 42 patients with
travel-related infections. Eating poultry is believed to be
the primary means of acquiring human campylobacterio-
sis, although other sources also exist (1). This corroborates
the hypothesis that quinolone-resistant–C. jejuni infections
could result from the use of quinolones in animals and in
food production. The veterinary antimicrobial drug use
hypothesis is supported by the findings of this study and
studies by our European and American colleagues that a
significantly higher proportion of quinolone-resistant C.
jejuni infections occur among patients who had been
abroad, often to destinations with recognized high
quinolone-resistance in Campylobacter in food animals as
well as established high risk of attracting quinolone-resist-
ant human Campylobacter infections, than among domes-
tically acquired infections (Tables 1 and 2) (3,11,12,18,
24–27). In Denmark, as part of the Danish Integrated
Antimicrobial Resistance Monitoring Programme (DAN-
MAP), antimicrobial drug susceptibility in Campylobacter
is monitored systematically in food animals, retail food
products, and humans as well as use of antimicrobial
drugs, including quinolones at food animal species level.
Compared to the practice in many other countries, only
small amounts of fluoroquinolones are used in broiler
chicken production, and during 2002, use of fluoro-
quinolones decreased significantly after restrictions
imposed by the Danish Veterinary and Food
Administration called for reducing fluoroquinolone use
(28). According to DANMAP surveillance data for 2002,
no resistance among C. jejuni to quinolones was found in
broiler chickens, and quinolone resistance to C. jejuni was
found in only 6% of imported and domestic retail chicken
meat (28). This finding may explain why eating fresh
chicken (of presumably Danish origin) was associated
with a decreased risk for quinolone-resistant C. jejuni
infection in the matched multivariate analysis. Our typing
data also support this explanation, because patients with
domestically acquired quinolone-sensitive C. jejuni infec-
tions were more likely to have a C. jejuni subtype that was
also identified among retail food products and broiler
chickens than were patients with domestically acquired
quinolone-resistant infections. 
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Table 4. Number of Campylobacter jejuni subtypes by quinolone susceptibility from domestically acquired infections, retail food 
products, and broiler chickens 
Origin
 a  Total no. subtypes 
Quinolone- 
resistant (%) 
Quinolone- 
sensitive (%) 
Quinolone-resistant and 
quinolone-sensitive (%) 
Humans (n = 496)  133  18 (13.5)  102 (76.7)  13 (9.8) 
Retail food products (n = 172)  81  9 (11.1)  70 (86.4)  2 (2.5) 
Broiler chickens (n = 46)  20  2 (10.0)  18 (90.0)  0 
Total  234  29 (12.4)  190 (81.2)  15 (6.4) 
aTen, 8, and 3 isolates from humans, retail food products, and broiler chickens, respectively, were not tested or nontypeable. A potential limitation of our study is the fact that only
one isolate from each retail food sample or broiler fecal
sample was characterized. Previous studies have shown
that multiple strains of Campylobacter may be recovered.
Capturing the diversity of strains may have been helpful
in accounting for a higher percentage of human strains, as
would analysis of additional food and broiler chicken
samples.
In many countries, including Denmark, fewer
Campylobacter infections are identified in the winter
months, but among the ones that are, a higher percentage
are associated with foreign travel. In the case-comparison
study, 30 (71%) of 42 quinolone-resistant C. jejuni infec-
tions were associated with foreign travel versus 66 (57%)
of 116 quinolone-resistant C. jejuni infections in the larger
study (not seasonal). A limitation of our study is therefore
its time frame (December–June). The patients with resist-
ant isolates in the case-comparison study were demograph-
ically (age and sex) comparable to the group of
quinolone-resistant infections from the larger study, which
were not included in the case-comparison study.
In the Minnesota study (14), a clinical implication of
fluoroquinolone-resistance among C. jejuni infections was
identified: the duration of diarrhea among patients treated
with a fluoroquinolone was significantly longer if the
patient had a fluoroquinolone-resistant infection (median
10 days) versus a fluoroquinolone-susceptible infection
(median 7 days). We also found significantly longer dura-
tion of illness among patients with quinolone-resistant C.
jejuni infections (median 13.2 days) compared to that of
patients with quinolone-sensitive infections (median 10.3
days). However, as history of antimicrobial treatment was
only obtained from the case-comparison proportion of our
study, stratifying by treatment to determine whether the
negative impact on public health was caused by true treat-
ment failures is not possible.
We found three macrolide-resistant strains; all were C.
coli isolated from travelers returning to Denmark. Our
finding is in line with current surveillance data on the level
of macrolide resistance in Danish broiler chickens, cattle,
and chicken meat (28). Resistance to macrolides has also
been reported at continued low level in a number of other
countries and should remain the first drug of choice for
verified campylobacteriosis (3,29).
In conclusion, the current study found evidence of pro-
longed duration of illness associated with quinolone resist-
ance and supports the conclusions drawn by the U.S. Food
and Drug Administration: human quinolone-resistant
Campylobacter  infections have increased, and this
increase has a negative impact on public health. This study
also suggests that in a country with restricted fluoro-
quinolone use in poultry production, chicken is not a
source of domestically acquired quinolone-resistant
Campylobacter infections, and that in countries with less
restrictive use, poultry is an important source of such
infections. The use of fluoroquinolones for food produc-
tion animals should be discontinued or minimized to pre-
serve fluoroquinolone sensitivity in Campylobacter.
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